No abstract available.
Hyperamylasemia* ; Sertraline*

OBJECT: This study was undertaken to know whether there is any therapeutic effecets of sertraline in treatment-resistant schizophrenics. METHOD: Seventy seven treatment-resistant schizophrenic patients, to whom the same antipsychotics as usual were administered, were randomly assigned to two groups; to the experimental group, sertraline was and to the controlled group, placebo was administered adjuntively for 6weeks in single blind design. We assessed psychopathology by BPRS, PANSS, YBOCS, HRSD, and SCL-90-R. RESULTS: BPRS, positive scale of PANSS, and HRSD were significantly decreased in experimental group and statistically siginificant differences between the experimental group and placebo group. Negative scale of PANSS and YBOCS were significantly decresed in experimental group but no statistically significant differences between the experimental group and placebo group. The therapeutic effect of sertraline was occurred within 3rd weeks. CONCLUSION: We suggested that sertraline may be useful in the treatment of schizophrenic symtom in treatment-resistent schizophrenia, especially in positive and depressive symptoms.
Antipsychotic Agents ; Depression ; Humans ; Psychopathology ; Schizophrenia ; Sertraline*

OBJECTIVE: To evaluate the clinical efficacy of adjuvant sertraline treatment in chronic schizophrenic patients, we carried out a double-blind, placebo controlled study. METHOD: Thirty six inpatients who fulfilled DSM-III-R criteria for chronic schizophrenia were randomly assigned to sertraline and placebo groups in a double-blinded fashion. A history of at least 2 years of illness and at least six months of hospitalization were prerequisities for inclusion in the study. Patients were received sertraline 50mg or placebo for 8 weeks in addition to their routine haloperidol regimen, Positive and Negative Syndrome Scale(PANSS), Clinical Global Impression(CGI), Simpson-Angus Scale(S-A) were evaluated at 5 points ; baseline, 2, 4, 6 and 8 weeks of treatment. RESULTS: The groups were controlled for age, gender, and length of illness. There were no significant differences in three PANSS factros(positive, negative, general), CGI and S-A scale scores at any between sertraline and placebo treatment. CONCLUSION: This placebo controlled study showed no significant effects of sertraline on negative and positive symptoms in chronic schizophrenic patients.
Haloperidol ; Hospitalization ; Humans ; Inpatients ; Schizophrenia* ; Sertraline*

This study investigated the antidepressant efficacy and it's impact on the quality of life of depressed patients. We performed Hamilton Depression Rating Scale(HDRS), and Montgomery-Asberg Depression Rating Scale(MADRS), and Health-related Quality of Life Questionnaire(HQLQ) to both tricyclic antidepressant(TCA) and sertraline groups. There were 16 subjects in the study. The tricyclic group had 9 subjects and the sertraline group had 7. The TCA and sertraline produced a similar degree of response. Both groups experienced a reduction of 70% or more in mean HDRS and MADRS total score after 6wks. In HQLQ, the TCAs group also showed improved bed disability days, alertness behavior, and social interaction, the sertraline group showed improved health perception, alertness behavior, home management, and social interaction. We suggested that the improvement of "Quality of life" were not in proportion to the clinical symptom's improvement. Therefore, clinicians should consider the benefit of antidepressant treatment in terms of quality of life.
Depression ; Humans ; Interpersonal Relations ; Quality of Life* ; Sertraline

The study was designed to evaluate the effects of sertraline on l% sucrose intake and weight change in rats with chronic unpredictable mild stress and normal controls. We applied 11 types of stress regimens and identified depressive behaviours in 18 Spraque-Dawley rats for 8 weeks. After 4 weeks of chronic unpredictable mild stress procedure, those 18 rats were stratified into a sertraline-treated subgroup and a saline subgroup. Also nonstressed 18 rats were stratified into the sertraline-treated subgroup and the saline subgroup and were started intraperitoneal injections of sertraline(4.29mg/Kg) or saline for rest of 4 weeks. The 1% sucrose intake and the body weight were checked on the 4th day of every week, over the 8 weeks of experiment. The results were as follows: 1) The sertraline-treated subgroup of chronic unpredictable mild stressed rats showed significant increase of 1% sucrose intake between the 1st week and the 2nd, the 3rd and 4th week, while the sertraline-treated subgroup of non-stressed rats showed decreasing trend for 1% sucrose intake. 2) The sertraline-treated subgroup of chronic unpredictable mild-stressed rats showed a sustained decrease of body weight, while the sertraline-treated subgroup of non-stressed rats showed a non-significant increase of body weight. 3) In the group subjected to chronic unpredictable mild stress, there were no significant correlations between 1% sucrose intake and body weight and also no correlations in the nonstressed group. In summary, sertraline had an effect on restoring the decreased 1% sucrose intake to normal condition but no effect on regaining the body weight in the chronic unpredictable mild stresstreated rats. Sertraline resulted in a decrease of l% sucrose intake and no effect on body weight in the non-stressed rats.
Animals ; Body Weight* ; Injections, Intraperitoneal ; Rats* ; Sertraline* ; Sucrose*

OBJECTIVE: It is important to predict a response to an antidepressant in early time after starting the antidepressant. We previously reported that serum brain-derived neurotrophic factor (BDNF) levels in responders to treatment with antidepressants were increased, whereas, those in nonresponders were not. Therefore, we hypothesized that the changes in serum levels of BDNF from baseline (T0) to 4 weeks (T4) after treatment with selective serotonin reuptake inhibitors (SSRIs) predict the response to the treatment at 8 weeks (T8) in depressed patients. To confirm the hypothesis, we measured serum BDNF at T0, T4, and T8 during the treatment with SSRIs (paroxetine, sertraline, and fluvoxamine). METHODS: One hundred fifty patients (M/F; 51/99, age; 50.4+/-15.1 years) met major depressive disorder (MDD) using by DSM-IV-TR enrolled in the present study. We measured serum BDNF concentrations at T0, T4, and T8 in patients with MDD treated with SSRIs. RESULTS: The changes in serum BDNF, age, sex, dose of SSRIs, and HAMD-17 score did not predict the response to SSRIs at T8. CONCLUSION: These results suggest that the changes in serum BDNF levels from T0 to T4 could not predict the subsequent responses to SSRIs at T8.
Antidepressive Agents ; Brain-Derived Neurotrophic Factor* ; Depression ; Depressive Disorder, Major ; Humans ; Serotonin Uptake Inhibitors ; Sertraline

OBJECTIVE: The effects of treatment with selective serotonin reuptake inhibitors (SSRIs) on serotonin (5-HT)-mediated Ca(2+) mobilization were investigated in the platelets of human healthy volunteers. METHOD: The serotonin (5-HT)-mediated Ca(2+) mobilization in the platelets was assessed by the fluorescence technique with fura-2/AM. RESULTS: SSRIs (fluoxetine, paroxetine and sertraline) themselves mobilized intracellular Ca(2+)([Ca(2+)]i) in a dose-dependent fashion. The increment of [Ca(2+)]i, might be induced partly by the release from the intracellular rat[ism store, but mostly induced by the calcium transport through membrane. Stimulation of platelets with 10 micrometer 5-HT caused a rapid and sustained increase in [Ca(2+)]i levels. Resting [Ca(2+)]i, before 5-HT treatment was 43.37+/-1.25 nM. Fluoxetine inhibited the increment of [Ca2+]i induced by 10 micrometer5-HT with an IC50 value of 6.36 micrometer. Paroxetine augmented 5-HT-mediated increases in [Ca2+]i, ranging from 117.76+/-2.79% to 316.22+/-8.39%, with an EC50 value of 19.68 micrometer. Sertraline also augmented 5-HT-mediated increases in [Ca(2+)]i in a dose-dependent fashion, ranging from 106.29+/-.40% to 269.29+/-4.96%, with an EC50it value of 11.40 micrometer. CONCLUSIONS: It is likely that SSRIs increase in intracellular free calcium level directly and show the inhibiting and augmenting effects on 5-HT-mediated Ca(2+) movements. The precise mechanisms underlying the effects of 5-HT-mediated[Ca(2+)]i response after treatment with SSRIs remain unclear however, the present finding suggests the possibility that a direct, or indirect, effort to intracellular Ca(2+) signaling may be at least partly involved in the mechanism of action of SSRIs.
Calcium ; Fluorescence ; Fluoxetine ; Healthy Volunteers ; Humans* ; Inhibitory Concentration 50 ; Membranes ; Paroxetine ; Serotonin Uptake Inhibitors ; Serotonin* ; Sertraline

OBJECTIVE: Since the Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) was developed in 2002, the third revision of KMAP-BP was performed in 2014 in order to reflect the recent rapid development and research of bipolar disorder and psychopharmacology. METHODS: According to methodology of previous versions, KMAP-BP 2014 was revised using the same questionnaire consisting of 14 questions. Sixty-four experts of the review committee completed the survey. The executive committee analyzed the results and discussed the final production of algorithm considering scientific evidence. RESULTS: The first-line pharmacotherapeutic strategy for acute bipolar depressive episode with moderate, non-psychotic severe and psychotic severe episode was mood stabilizer combined with atypical antipsychotic (AAP) or AAP with lamotrigine. Compared to KMAP-BP 2010, preference of AAP has been increased in the treatment of bipolar depressive episode in KMAP-BP 2014. Among AAPs, olanzapine, quetiapine and aripiprazole were preferred. When considering the efficacy and safety simultaneously, (es)citalopram, bupropion, and sertraline were recommended among antidepressants for bipolar depression. CONCLUSION: Compared with the previous version, we found that more aggressive pharmacological strategies as an initial treatment were preferred, although various strategies were recommended as same as previous studies. Increased preference of AAP was prominent in KMAP-BP 2014. We expect this algorithm may be helpful in the treatment of bipolar disorder, depressive episode.
Advisory Committees ; Antidepressive Agents ; Bipolar Disorder* ; Bupropion ; Drug Therapy ; Psychopharmacology ; Surveys and Questionnaires ; Sertraline ; Aripiprazole ; Quetiapine Fumarate

OBJECTIVE: This study was conducted to evaluate effects of sertraline treatment on symptoms and memory function of posttraumatic stress disorder (PTSD). METHODS: Thirty Vietnam veterans were collected for this study, among whom fifteen were PTSD patients and fifteen were combat control subjects. We used Mississippi Scale for Combat-Related PTSD, Combat Exposure Scale (CES), Hamilton Depression Rating Scale (HDRS) and Clinician Administered PTSD Scale (CAPS). Digit Span, Paired Association Learning Test (PALT) and Rey- Osterreith Complex Figure Test (CFT) were assessed for memory function. We evaluated HDRS, CAPS and memory function tests at baseline, 2-week and 6-week intervals with each subjects. RESULTS: There were significant differences between PTSD and Non-PTSD veterans in Mississippi Scale for Combat-Related PTSD, CES, HDRS and CAPS. Significant difference was found in memory function tests between PTSD and Non-PTSD veterans. PTSD veterans showed significant improvement in HDRS and CAPS at 2-week and 6-week and in memory function tests at 6-week of sertraline treatment. There was no significant correlation between symptoms and memory function. CONCLUSION: These results suggest that sertraline improve symptoms and memory function of PTSD. There was no significant correlation between PTSD sysmtoms and memory function.
Association Learning ; Depression ; Humans ; Memory* ; Mississippi ; Sertraline* ; Stress Disorders, Post-Traumatic* ; Veterans ; Vietnam

OBJECTIVE: This study was designed to evaluate the efficacy and safety of tianeptine and sertraline in the treatment of patients with depression. METHOD: The study was done on the patients with major depression diagnosed by DSM-IV, who had a Hamilton Rating Scale for Depression(HAM-D) score > OR =14 on the first 17 items of the HAM-D. A total of 40 patients were randomly assigned to tianeptine group and sertraline group. Tianeptine and sertraline were prescribed to each group. 6 weeks of each medication was carried out after 7 days of drug excretion period. Evaluation using 17 item HAM-D, Montgomery and {0c5}sberg Depression Rating Scale(MADRS), Clinical Global Impression Scale(CGI), and Covi Scale was done on the baseline and after 1 week, 2 weeks, 4 weeks, and 6 weeks. Regarding all side effects that had occurred during the period of our study such as their developed/disappeared time, severities, incidences, managements and results have been recorded. RESULTS: A total of 30 patients(tianeptine group 15;sertraline group 15) finished the 6 weeks of research. 37.5mg of the daily dose was regularly prescribed to the tianeptine group, the average amount of 64.0+/-22.5mg of the final daily dose was prescribed to the sertraline group. Total 17 item HAM-D scores, total points of MADRS and CGI showed significant decrease after 1 week in each treatment group and continous decrease after 2, 4 and 6 weeks;and no difference was found between tianeptine group and sertraline group in the antidepressant efficacy. Also there were no significant changes in vital sign, CBC, chemistry, and EKG in each treatment group. The common reported side effects of tianeptine were nausea(33.3%), epigastic distress(26.7%), dry mouth(20.0%), headache(13.3%) and those of sertraline were dry mouth(53.3%), headache(46.7%), nausea(33.3%), anorexia(33.3%). CONCLULSION: According to the results, tianeptine was effective in improvement of depressive symptoms and was well tolerated and safe in patients with depression.
Chemistry ; Depression* ; Diagnostic and Statistical Manual of Mental Disorders ; Electrocardiography ; Humans ; Incidence ; Sertraline* ; Vital Signs